

# Open-angle glaucoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/O47628E6763EN.html>

Date: May 2021

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: O47628E6763EN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Open-angle glaucoma - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Open-angle glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Open-angle glaucoma Understanding

#### Open-angle glaucoma: Overview

Glaucoma is an eye disease that gradually steals vision. Open-angle glaucoma is the most common type of glaucoma. Open-angle glaucoma is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by an open angle of the anterior chamber, optic nerve head changes, progressive loss of peripheral vision, followed by central visual field loss. Glaucoma affects 70 million people worldwide and is the second leading cause of blindness. The underlying pathology of Open-angle glaucoma lies in the apoptosis of retinal ganglion cells. Open-angle glaucoma can be clinically evaluated using a variety of diagnostic tools including optic disc changes, visual field changes, and elevated intraocular pressure. The goal of treatment of open-angle glaucoma is to prevent the progression of optic nerve head changes and also the

prevention of deterioration of visual field.

'Open-angle glaucoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Open-angle glaucoma pipeline landscape is provided which includes the disease overview and Open-angle glaucoma treatment guidelines. The assessment part of the report embraces, in depth Open-angle glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Open-angle glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Open-angle glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Open-angle glaucoma.

### Open-angle glaucoma Emerging Drugs Chapters

This segment of the Open-angle glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Open-angle glaucoma Emerging Drugs

#### QLS-101: Qlaris Bio

QLS-101 is a novel topical ocular therapy that lowers intraocular pressure. QLS-101 modulates KATP channel by relaxing vessels of the vascular and vascular-like tissues distal to the Trabecular Meshwork, thereby reducing distal outflow resistance and lowering Episcleral Venous Pressure (EVP). Qlaris Bio has initiated clinical studies with QLS-101 in patients with Primary Open Angle Glaucoma, Ocular Hypertension, Normal

Tension Glaucoma, and Sturge-Weber syndrome.

#### Razuprotafib: Aerpio Pharmaceuticals

Razuprotafib is a novel small molecule Tie2 activator that enhances endothelial function and stabilizes blood vessels, including pulmonary and renal vasculature. Razuprotafib (AKB-9778) topical drops is currently under Phase II clinical evaluation for treatment of primary open angle glaucoma (POAG).

Further product details are provided in the report

#### Open-angle glaucoma: Therapeutic Assessment

This segment of the report provides insights about the different Open-angle glaucoma drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Open-angle glaucoma

There are approx. 20+ key companies which are developing the therapies for Open-angle glaucoma. The companies which have their Open-angle glaucoma drug candidates in the most advanced stage, i.e. Phase III include, Ocular Therapeutix.

#### Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Open-angle glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## Open-angle glaucoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Open-angle glaucoma therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Open-angle glaucoma drugs.

## Open-angle glaucoma Report Insights

- Open-angle glaucoma Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

## Open-angle glaucoma Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

## Key Questions

## Current Treatment Scenario and Emerging Therapies:

How many companies are developing Open-angle glaucoma drugs?

How many Open-angle glaucoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Open-angle glaucoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Open-angle glaucoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Open-angle glaucoma and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Qlaris Bio

Ocular Therapeutix

SALVAT

Aerpio Pharmaceuticals

Ocularis Pharma

PolyActiva

AbbVie

Annexon

Skye Bioscience

GrayBug

Quark Pharmaceuticals

## Key Products

QLS-101

Travoprost ophthalmic

SVT18412

Razuprotafib

Phentolamine

PA5108

AGN 193408 sustained-release

ANX 007

NB 1111

GB 401

QPI-1017

## Contents

Introduction

Executive Summary

Open-angle glaucoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Open-angle glaucoma – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Open-angle glaucoma companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Open-angle glaucoma Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Travoprost ophthalmic: Ocular Therapeutix

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

QLS-101: Qlaris Bio

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I/II)

Comparative Analysis

PA5108: PolyActiva

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Preclinical and Discovery Stage Products

Comparative Analysis

NB 1111: Skye Bioscience

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Open-angle glaucoma Key Companies

Open-angle glaucoma Key Products

Open-angle glaucoma- Unmet Needs

Open-angle glaucoma- Market Drivers and Barriers

Open-angle glaucoma- Future Perspectives and Conclusion

Open-angle glaucoma Analyst Views

Open-angle glaucoma Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Open-angle glaucoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Open-angle glaucoma

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Open-angle glaucoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/O47628E6763EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O47628E6763EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970